144 related articles for article (PubMed ID: 36244565)
21. Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
Kimura T; Nakamura K; Miyoshi T; Yoshida M; Akazawa K; Saito Y; Akagi S; Ohno Y; Kondo M; Miura D; Wada J; Ito H
Int Heart J; 2019 May; 60(3):728-735. PubMed ID: 31105148
[TBL] [Abstract][Full Text] [Related]
22. Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction.
Çamcı S; Yılmaz E
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013595
[TBL] [Abstract][Full Text] [Related]
23. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Chowdhury B; Luu AZ; Luu VZ; Kabir MG; Pan Y; Teoh H; Quan A; Sabongui S; Al-Omran M; Bhatt DL; Mazer CD; Connelly KA; Verma S; Hess DA
Biochem Biophys Res Commun; 2020 Mar; 524(1):50-56. PubMed ID: 31980166
[TBL] [Abstract][Full Text] [Related]
24. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload.
Raher MJ; Thibault HB; Buys ES; Kuruppu D; Shimizu N; Brownell AL; Blake SL; Rieusset J; Kaneki M; Derumeaux G; Picard MH; Bloch KD; Scherrer-Crosbie M
Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2495-502. PubMed ID: 18978196
[TBL] [Abstract][Full Text] [Related]
25. The novel P2X7 receptor antagonist PKT100 improves cardiac function and survival in pulmonary hypertension by direct targeting of the right ventricle.
Hansen T; Karimi Galougahi K; Besnier M; Genetzakis E; Tsang M; Finemore M; O'Brien-Brown J; Di Bartolo BA; Kassiou M; Bubb KJ; Figtree GA
Am J Physiol Heart Circ Physiol; 2020 Jul; 319(1):H183-H191. PubMed ID: 32469637
[TBL] [Abstract][Full Text] [Related]
26. Mechanical stretching of pulmonary vein stimulates matrix metalloproteinase-9 and transforming growth factor-β1 through stretch-activated channel/MAPK pathways in pulmonary hypertension due to left heart disease model rats.
Zhang H; Huang W; Liu H; Zheng Y; Liao L
PLoS One; 2020; 15(9):e0235824. PubMed ID: 32881898
[TBL] [Abstract][Full Text] [Related]
27. Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling.
Mori Y; Terasaki M; Hiromura M; Saito T; Kushima H; Koshibu M; Osaka N; Ohara M; Fukui T; Ohtaki H; Tsutomu H; Yamagishi SI
Cardiovasc Diabetol; 2019 Oct; 18(1):143. PubMed ID: 31672147
[TBL] [Abstract][Full Text] [Related]
28. Mechanical stretching of the pulmonary vein mediates pulmonary hypertension due to left heart disease by regulating SAC/MAPK pathway and the expression of IL-6 and TNF-α.
Huang W; Liu H; Pan Y; Yang H; Lin J; Zhang H
J Cardiothorac Surg; 2021 May; 16(1):127. PubMed ID: 33971931
[TBL] [Abstract][Full Text] [Related]
29. Nitric oxide synthase 3 deficiency limits adverse ventricular remodeling after pressure overload in insulin resistance.
Kurtz B; Thibault HB; Raher MJ; Popovich JR; Cawley S; Atochin DN; Hayton S; Shakartzi HR; Huang PL; Bloch KD; Buys E; Scherrer-Crosbie M
Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H2093-101. PubMed ID: 21856905
[TBL] [Abstract][Full Text] [Related]
30. Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload.
Nakao M; Shimizu I; Katsuumi G; Yoshida Y; Suda M; Hayashi Y; Ikegami R; Hsiao YT; Okuda S; Soga T; Minamino T
Sci Rep; 2021 Sep; 11(1):18384. PubMed ID: 34526601
[TBL] [Abstract][Full Text] [Related]
31. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
Lan NSR; Fegan PG; Yeap BB; Dwivedi G
ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
[TBL] [Abstract][Full Text] [Related]
32. The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis.
Moellmann J; Mann PA; Kappel BA; Kahles F; Klinkhammer BM; Boor P; Kramann R; Ghesquiere B; Lebherz C; Marx N; Lehrke M
Diabetes Obes Metab; 2022 Nov; 24(11):2263-2272. PubMed ID: 35801343
[TBL] [Abstract][Full Text] [Related]
33. The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
Shimohata H; Iwaki Y; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
Int Urol Nephrol; 2022 Aug; 54(8):1907-1914. PubMed ID: 34843041
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice.
Hanaguri J; Yokota H; Kushiyama A; Kushiyama S; Watanabe M; Yamagami S; Nagaoka T
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163285
[TBL] [Abstract][Full Text] [Related]
35. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
[TBL] [Abstract][Full Text] [Related]
36. An updated review of experimental rodent models of pulmonary hypertension and left heart disease.
Jasińska-Stroschein M
Front Pharmacol; 2023; 14():1308095. PubMed ID: 38259266
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease.
Hunt JM; Bethea B; Liu X; Gandjeva A; Mammen PP; Stacher E; Gandjeva MR; Parish E; Perez M; Smith L; Graham BB; Kuebler WM; Tuder RM
Am J Physiol Lung Cell Mol Physiol; 2013 Nov; 305(10):L725-36. PubMed ID: 24039255
[TBL] [Abstract][Full Text] [Related]
38. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of pulmonary hypertension caused by left heart disease.
Xiao M; Lai D; Yu Y; Wu Q; Zhang C
Front Cardiovasc Med; 2023; 10():1079142. PubMed ID: 36937903
[TBL] [Abstract][Full Text] [Related]
40. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
Iwamoto M; Kubota T; Sakurai Y; Wada N; Shioda S; Yamauchi T; Kadowaki T; Kubota N
Pharmacol Res Perspect; 2022 Aug; 10(4):e00971. PubMed ID: 35707828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
